Gelatine tannate in the management of acute gastroenteritis in children: a randomised controlled trial

Maciej Kołodziej, Dorota Bebenek, Zofia Konarska, Hania Szajewska, Maciej Kołodziej, Dorota Bebenek, Zofia Konarska, Hania Szajewska

Abstract

Objective: To assess the efficacy of gelatine tannate (a complex of tannic acid with astringent and anti-inflammatory properties, and a protective gelatine) for the treatment of acute gastroenteritis (AGE) in children.

Design: Randomised, double-blind, placebo-controlled trial. Intention-to-treat analysis.

Setting: Two paediatric hospitals in Warsaw.

Participants: Children younger than 5 years of age with AGE, defined as a change in stool consistency to a loose or liquid form (according to the Bristol Stool Form Scale or Amsterdam Stool Form Scale) and/or an increase in the frequency of evacuations (≥3 in 24 hours), lasting for no longer than 5 days.

Interventions: Seventy-two children were assigned to receive gelatine tannate (n=36) or placebo (n=36) in addition to standard rehydration therapy. The gelatine tannate was administered at an age-dependent dose (250-500 mg), and both study products were taken four times per day for 5 days.

Primary and secondary outcome measures: The main outcome measure was duration of diarrhoea. Secondary outcomes included the need for intravenous rehydration, need for hospitalisation of outpatients, number of watery stools per day, vomiting, weight gain, adverse events, recurrence of diarrhoea, severity of diarrhoea according to the Vesikari Scale and use of concomitant medications.

Results: Sixty-four children (89%) completed the intervention and were included in the analysis. The duration of diarrhoea after randomisation was similar in the gelatine tannate and placebo groups (75.6±27.8 vs 75.5±29.0 hours, respectively, mean difference 0.1 hours, 95% CI -14.1 to 14.3 hours). There was no significant difference between groups in the number of watery stools per day throughout the study period. There were also no differences in any other secondary outcome measures between groups.

Conclusion: In children with AGE younger than 5 years of age, gelatine tannate was ineffective as an adjunct to rehydration therapy.

Trial registration number: NCT02280759.

Keywords: antidiarrhoeal drugs; diarrhoea; rehydration.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Flow diagram.

References

    1. Guarino A, Ashkenazi S, Gendrel D, et al. . European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014;59:132–52. 10.1097/MPG.0000000000000375
    1. Bueno L, Sekkal S, Theodoru V, et al. . Undissociated gelatin tannate reduces intestinal leakiness and mucosa inflammation by forming a protective biofilm: results from in-vitro and in-vivo studies. Gastroenterol J 2013;1(Suppl 1):A75.
    1. Chung K-T, Jr SES, Lin W-F, et al. . Growth inhibition of selected food-borne bacteria by tannic acid, propyl gallate and related compounds. Lett Appl Microbiol 1993;17:29–32. 10.1111/j.1472-765X.1993.tb01428.x
    1. Scalbert A. Antimicrobial properties of tannins. Phytochemistry 1991;30:3875–83. 10.1016/0031-9422(91)83426-L
    1. Oi H, Matsuura D, Miyake M, et al. . Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc Natl Acad Sci U S A 2002;99:3042–6. 10.1073/pnas.052709499
    1. Frasca G, Cardile V, Puglia C, et al. . Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells. Clin Exp Gastroenterol 2012;5:61–7. 10.2147/CEG.S28792
    1. Ruszczyński M, Urbańska M, Szajewska H. Gelatin tannate for treating acute gastroenteritis: a systematic review. Ann Gastroenterol 2014;27:121–4.
    1. Michałek D, Kołodziej M, Konarska Z, et al. . Efficacy and safety of gelatine tannate for the treatment of acute gastroenteritis in children: protocol of a randomised controlled trial. BMJ Open 2016;6:e010530 10.1136/bmjopen-2015-010530
    1. Moher D, Hopewell S, Schulz KF, et al. . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869 10.1136/bmj.c869
    1. WHO. The WHO child growth standards.
    1. Schnadower D, Tarr PI, Gorelick MH, et al. . Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr 2013;57:514–9. 10.1097/MPG.0b013e31829ae5a3
    1. Sealed Envelope Ltd. Power calculator for continuous outcome superiority trial. 2012. (accessed 2 Nov 2015).
    1. Mennini M, Tolone C, Frassanito A, et al. . Gelatin tannate for acute childhood gastroenteritis: a randomized, single-blind controlled trial. Paediatr Drugs 2017;19:131–7. 10.1007/s40272-016-0207-z
    1. Çağan E, Ceylan S, Mengi Ş, et al. . Evaluation of gelatin tannate against symptoms of acute diarrhea in pediatric patients. Med Sci Monit 2017;23:2029–34. 10.12659/MSM.903158
    1. Shane AL, Mody RK, Crump JA, et al. . 2017 infectious diseases society of america clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis 2017;65:1963–73. 10.1093/cid/cix959

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe